Table 4. Cancer staging comparison Apr 2020 to Sep 2020 versus Oct 2019 to Mar 2020. Number of cases and percentage breakdown at Stages 1–4.
| Oct 2019 to Mar 2020 | Apr 2019 to Sep 2020 | |||||||
|---|---|---|---|---|---|---|---|---|
| Tumour group | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 1 | Stage 2 | Stage 3 | Stage 4 |
| Breast | 93 | 69 | 46 | 25 | 55 | 66 | 31 | 23 |
| Colorectal | 21 | 32 | 75 | 41 | 10 | 10 | 37 | 20 |
| Lung | 77 | 21 | 51 | 89 | 45 | 16 | 29 | 85 |
| Prostate | 38 | 221 | 84 | 55 | 18 | 66 | 25 | 23 |
| Overall | 229 | 343 | 256 | 210 | 128 | 158 | 122 | 151 |
| Oct 2019 to Mar 2020 | Apr 2019 to Sep 2020 | Variance (Stage 4) | Greatest shift between stages |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tumour group | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 1 | Stage 2 | Stage 3 | Stage 4 | ||
| Breast | 39.9% | 29.6% | 19.7% | 10.7% | 31.4% | 37.7% | 17.7% | 13.1% | +2.4 | 1–2 |
| Colorectal | 12.4% | 18.9% | 44.4% | 24.3% | 13.0% | 13.0% | 48.1% | 26.0% | +1.7 | 2–3 |
| Lung | 32.4% | 8.8% | 21.4% | 37.4% | 25.7% | 9.1% | 16.6% | 48.6% | +11.2 | 3–4 |
| Prostate | 9.5% | 55.5% | 21.1% | 13.8% | 13.6% | 50.0% | 18.9% | 17.4% | +3.6 | 3–4 |
| Overall | 22.1% | 33.0% | 24.7% | 20.2% | 22.9% | 28.3% | 21.8% | 27.0% | +6.8 | 3–4 |